Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;165(3):344-53.e1.
doi: 10.1016/j.ahj.2012.09.008.

TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium

Connie N Hess  1 , Sunil V Rao, David F Kong, Julie M Miller, Kevin J Anstrom, Olivier F Bertrand, Jean-Philippe Collet, Mark B Effron, Benjamin C Eloff, Emmanuel O Fadiran, Andrew Farb, Ian C Gilchrist, David R Holmes, Alice K Jacobs, Prashant Kaul, L Kristin Newby, David R Rutledge, Dale R Tavris, Thomas T Tsai, Roseann M White, Eric D Peterson, Mitchell W Krucoff
Affiliations

TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium

Connie N Hess et al. Am Heart J. 2013 Mar.

Abstract

Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery disease. The most common complication of PCI, bleeding, typically occurs at the vascular access site and is associated with short-term and long-term morbidity and mortality. Periprocedural bleeding also represents the primary safety concern of concomitant antithrombotic therapies essential for PCI success. Use of radial access for PCI reduces procedural bleeding and hence may change the risk profile and net clinical benefit of these drugs. This new drug-device safety interaction creates opportunities to advance the safe and effective use of antithrombotic agents during PCI. In June 2010 and March 2011, leaders from government, academia, professional societies, device manufacturing, and pharmaceutical industries convened for 2 think tank meetings. Titled TREAT I and II, these forums examined approaches to improve the overall safety of PCI by optimizing strategies for antithrombotic drug use and radial artery access. This article summarizes the content and proceedings of these sessions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bleeding and vascular complications after PCI in men vs women. rPCI, radial PCI; f-PCI, femoral PCI. From Rao et al.
Figure 2
Figure 2
Temporal trends in use of radial PCI in the United States since 2007. Data courtesy of NCDR. QTR, quarter.
Figure 3
Figure 3
Timeline of events.
See this image and copyright information in PMC

References

    1. Talbot JCC, Aronson JK, Stephens MDB. Stephens’ detection and evaluation of adverse drug reactions: principles and practice. John Wiley & Sons; Chichester, West Sussex, UK: 2011.
    1. Fung M. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets—1960 to 1999. Drug Inf J. 2001;35:293–317.
    1. Piccini JP, Whellan DJ, Berridge BR, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative. Am Heart J. 2009;158:317–26. - PubMed
    1. FDA . Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Food and Drug Administration, U.S. Department of Health and Human Services; Washington, DC: 2004.
    1. Al-Khatib SM, Calkins H, Eloff BC, et al. Developing the safety of atrial fibrillation ablation registry initiative (safari) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium “incubator” think tank. Am Heart J. 2010;160:619–26. - PubMed

Publication types

MeSH terms

Substances